Literature DB >> 31926847

Deciphering the concepts behind "Epileptic encephalopathy" and "Developmental and epileptic encephalopathy".

Ingrid E Scheffer1, Jianxiang Liao2.   

Abstract

The recent introduction of the term 'developmental and epileptic encephalopathy' by the International League Against Epilepsy has added another conceptual layer to understanding the most severe group of epilepsies. An epileptic encephalopathy is defined by the presence of frequent epileptiform activity that impacts adversely on development, typically causing slowing or regression of developmental skills, and usually associated with frequent seizures. Many of the epileptic encephalopathies are now known to have an identifiable molecular genetic basis. The term 'developmental' was introduced as there are multiple facets leading to developmental impairment in affected individuals. The underlying genetic cause often results in developmental delay in its own right, with the epileptic encephalopathy further adversely affecting development. Treatment of the epileptic encephalopathy may improve developmental progress, so early recognition and active management are essential to improve developmental outcomes. Equally, understanding that the genetic aetiology independently leads to developmental impairment means that precision therapies need to be holistic in addressing the devastating consequences of this group of diseases.
Copyright © 2019. Published by Elsevier Ltd.

Entities:  

Keywords:  Developmental and epileptic encephalopathy; Developmental encephalopathy; Epilepsy syndrome; Epileptic encephalopathy; Regression

Year:  2019        PMID: 31926847     DOI: 10.1016/j.ejpn.2019.12.023

Source DB:  PubMed          Journal:  Eur J Paediatr Neurol        ISSN: 1090-3798            Impact factor:   3.140


  18 in total

1.  Impact of Genetic Testing on Therapeutic Decision-Making in Childhood-Onset Epilepsies-a Study in a Tertiary Epilepsy Center.

Authors:  Allan Bayat; Christina D Fenger; Tanya R Techlo; Anne F Højte; Ida Nørgaard; Thomas F Hansen; Guido Rubboli; Rikke S Møller; Danish Cytogenetic Central Registry Study Group
Journal:  Neurotherapeutics       Date:  2022-06-20       Impact factor: 6.088

2.  Soticlestat, a novel cholesterol 24-hydroxylase inhibitor, reduces seizures and premature death in Dravet syndrome mice.

Authors:  Nicole A Hawkins; Manuel Jurado; Tyler T Thaxton; Samantha E Duarte; Levi Barse; Tetsuya Tatsukawa; Kazuhiro Yamakawa; Toshiya Nishi; Shinichi Kondo; Maki Miyamoto; Brett S Abrahams; Matthew J During; Jennifer A Kearney
Journal:  Epilepsia       Date:  2021-09-12       Impact factor: 6.740

Review 3.  Natural History Studies and Clinical Trial Readiness for Genetic Developmental and Epileptic Encephalopathies.

Authors:  Elizabeth E Palmer; Katherine Howell; Ingrid E Scheffer
Journal:  Neurotherapeutics       Date:  2021-10-27       Impact factor: 6.088

4.  Early-infantile onset epilepsy and developmental delay caused by bi-allelic GAD1 variants.

Authors:  Caroline Neuray; Reza Maroofian; Marcello Scala; Tipu Sultan; Gurpur S Pai; Majid Mojarrad; Heba El Khashab; Leigh deHoll; Wyatt Yue; Hessa S Alsaif; Maria N Zanetti; Oscar Bello; Richard Person; Atieh Eslahi; Zaynab Khazaei; Masoumeh H Feizabadi; Stephanie Efthymiou; Hala T El-Bassyouni; Doaa R Soliman; Selahattin Tekes; Leyla Ozer; Volkan Baltaci; Suliman Khan; Christian Beetz; Khalda S Amr; Vincenzo Salpietro; Yalda Jamshidi; Fowzan S Alkuraya; Henry Houlden
Journal:  Brain       Date:  2020-08-01       Impact factor: 13.501

5.  SCN8A Encephalopathy: Case Report and Literature Review.

Authors:  Hueng-Chuen Fan; Hsiu-Fen Lee; Ching-Shiang Chi
Journal:  Neurol Int       Date:  2021-04-01

6.  Pediatric Encephalopathy: Clinical, Biochemical and Cellular Insights into the Role of Gln52 of GNAO1 and GNAI1 for the Dominant Disease.

Authors:  Gonzalo P Solis; Tatyana V Kozhanova; Alexey Koval; Svetlana S Zhilina; Tatyana I Mescheryakova; Aleksandr A Abramov; Evgeny V Ishmuratov; Ekaterina S Bolshakova; Karina V Osipova; Sergey O Ayvazyan; Sébastien Lebon; Ilya V Kanivets; Denis V Pyankov; Sabina Troccaz; Denis N Silachev; Nikolay N Zavadenko; Andrey G Prityko; Vladimir L Katanaev
Journal:  Cells       Date:  2021-10-14       Impact factor: 6.600

7.  Expanding the phenotype of PIGS-associated early onset epileptic developmental encephalopathy.

Authors:  Stephanie Efthymiou; Marina Dutra-Clarke; Reza Maroofian; Rauan Kaiyrzhanov; Marcello Scala; Javeria Reza Alvi; Tipu Sultan; Marilena Christoforou; Thi Tuyet Mai Nguyen; Kshitij Mankad; Barbara Vona; Aboulfazl Rad; Pasquale Striano; Vincenzo Salpietro; Maria J Guillen Sacoto; Maha S Zaki; Joseph G Gleeson; Philippe M Campeau; Bianca E Russell; Henry Houlden
Journal:  Epilepsia       Date:  2021-01-07       Impact factor: 6.740

Review 8.  Brain Symptoms of Tuberous Sclerosis Complex: Pathogenesis and Treatment.

Authors:  Masashi Mizuguchi; Maki Ohsawa; Hirofumi Kashii; Atsushi Sato
Journal:  Int J Mol Sci       Date:  2021-06-22       Impact factor: 5.923

Review 9.  Precision medicine and therapies of the future.

Authors:  Sanjay M Sisodiya
Journal:  Epilepsia       Date:  2020-07-24       Impact factor: 6.740

Review 10.  Epilepsy Syndromes in the First Year of Life and Usefulness of Genetic Testing for Precision Therapy.

Authors:  Allan Bayat; Michael Bayat; Guido Rubboli; Rikke S Møller
Journal:  Genes (Basel)       Date:  2021-07-08       Impact factor: 4.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.